EUVIMEDEUVIMED entdecken
Fallbericht

Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus–Associated Meningoencephalitis

Sana Ahsan iD, Saba Jafarpour, Mellad M Khoshnood iD, Deepti Nagesh, Eugenia Ho, Nusrat Ahsan iD, Jonathan D Santoro iD

Journal of Child Neurology · 2025

DOI: 10.1177/08830738241276972 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Child Neurology, 2025. Verfasst von Sana Ahsan und 6 weiteren Autor:innen. Beteiligte Einrichtung: California University of Science and Medicine, Colton, CA, USA. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Meningoencephalitis, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein-Barr virus meningoencephalitis is a rare central nervous system infection that lacks standardized treatment. Immunocompetent and immunosuppressed individuals with this condition frequently have poor prognostic outcomes, making the need to identify therapeutic interventions high. Here, we report 2 pediatric cases of severe Epstein-Barr virus meningoencephalitis, both unresponsive to immunoglobulin and corticosteroid therapy, who demonstrated rapid clinical recovery following rituximab administration. Prognostic outcomes revealed marked improvements in symptoms, neurologic function, and quality of life. Rituximab may offer therapeutic potential in severe and refractory Epstein-Barr virus meningoencephalitis through the medication's target of Epstein-Barr virus harboring B cells. This report emphasizes the need for timely evaluation and consideration of rituximab therapy in immunocompetent pediatric patients with Epstein-Barr virus meningoencephalitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsMeningoencephalitisRituximabChildChild, PreschoolFemaleHumansMaleAntigens, CD20Herpesvirus 4, HumanImmunologic Factors

Stichwörter der Autor:innen

CD20Epstein-Barr virusencephalitismeningoencephalitisrituximab

Substanzen

Antigens, CD20Immunologic FactorsRituximab

Autor:innen und Institutionen

  • California University of Science and Medicine, Colton, CA, USA.
  • Division of Neurology, Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  • Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

ORCID-Profile: Sana Ahsan, Mellad M Khoshnood, Nusrat Ahsan, Jonathan D Santoro

Zitieren

APA

Ahsan, S., Jafarpour, S., Khoshnood, M. M., Nagesh, D., Ho, E., Ahsan, N., & Santoro, J. D. (2025). Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus–Associated Meningoencephalitis. Journal of Child Neurology. https://doi.org/10.1177/08830738241276972

Vancouver

Ahsan S, Jafarpour S, Khoshnood MM, Nagesh D, Ho E, Ahsan N, et al. Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus–Associated Meningoencephalitis. Journal of Child Neurology. 2025. doi:10.1177/08830738241276972

BibTeX
@article{Ahsan2025,
  author = {Ahsan, Sana and Jafarpour, Saba and Khoshnood, Mellad M and Nagesh, Deepti and Ho, Eugenia and Ahsan, Nusrat and Santoro, Jonathan D},
  title = {Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus–Associated Meningoencephalitis},
  journal = {Journal of Child Neurology},
  year = {2025},
  doi = {10.1177/08830738241276972}
}
Kostenlos starten →